Akebia Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	162.64	184.84	51.87	42.93	90.47	149.8
Cash & Short-Term Investments	162.64	184.84	51.87	42.93	90.47	149.8
Cash Growth	43.46%	256.36%	20.84%	-52.55%	-39.61%	-44.25%
Accounts Receivable	62.54	47.03	34.37	39.29	40.28	51.58
Inventory	13	15.61	16.24	15.69	21.57	36.63
Other Current Assets	5.31	5.47	11.35	20.24	32.86	33.14
Total Current Assets	243.48	252.96	113.83	118.15	185.18	271.15
Net Property, Plant & Equipment	3.42	4.89	10.42	16.05	34.37	40.61
Other Intangible Assets	-	-	-	36.04	72.08	108.13
Goodwill	59.04	59.04	59.04	59.04	59.04	59.04
Other Long-Term Assets	56.57	59.68	37.38	12.42	5.37	50.42
Total Assets	362.52	376.57	220.67	241.7	356.05	529.35
Accounts Payable	8.39	21.19	15.18	14.64	18.02	33.59
Accrued Expenses	125.06	121.72	63.46	67.74	75.78	109.01
Current Portion of Long-Term Debt	12.5	-	-	17.5	32	97.54
Unearned Revenue	4.5	2.68	-	-	3.74	20.91
Other Current Liabilities	23.45	17.36	2.27	-	-	-
Total Current Liabilities	173.88	162.94	80.91	99.87	129.54	261.05
Long-Term Debt	36.4	48.25	38.69	17.18	34.08	-
Long-Term Leases	-	-	3.55	8.95	28.96	33.7
Other Long-Term Liabilities	124.87	132.77	146.7	146.29	158.25	160.59
Total Long-Term Liabilities	161.26	181.02	188.94	172.42	221.29	194.29
Total Liabilities	335.15	343.96	269.86	272.29	350.82	455.34
Common Stock	0	0	0	0	0	0
Additional Paid-in Capital	1,720	1,716	1,629	1,578	1,562	1,537
Accumulated Other Comprehensive Income	0.01	0.01	0.01	0.01	0.01	0.01
Retained Earnings	-1,693	-1,684	-1,678	-1,609	-1,557	-1,463
Shareholders' Equity	27.38	32.61	-49.19	-30.58	5.23	74.01
Total Liabilities & Equity	362.52	376.57	220.67	241.7	356.05	529.35
Total Debt	48.89	48.25	42.24	43.63	95.04	131.25
Net Cash (Debt)	113.75	136.59	9.63	-0.71	-4.57	18.55
Net Cash Growth	-16.72%	1318.42%	-	-	-	-87.44%
Net Cash Per Share	0.42	0.53	0.05	-0.00	-0.03	0.11
Book Value	27.38	32.61	-49.19	-30.58	5.23	74.01
Book Value Per Share	0.10	0.13	-0.23	-0.16	0.03	0.45
Tangible Book Value	-31.67	-26.43	-108.23	-125.67	-125.9	-93.16
Tangible Book Value Per Share	-0.12	-0.10	-0.51	-0.67	-0.69	-0.56

SEC Filings: 10-K · 10-Q